Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Assets (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Current Assets for 7 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 44.47% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 44.47% year-over-year, with the annual reading at $1.3 billion for FY2025, 44.47% up from the prior year.
  • Current Assets for Q4 2025 was $1.3 billion at Beam Therapeutics, up from $1.1 billion in the prior quarter.
  • The five-year high for Current Assets was $1.3 billion in Q4 2021, with the low at $514.6 million in Q1 2021.
  • Average Current Assets over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 351.07% in 2021, then dropped 27.49% in 2024.
  • Over 5 years, Current Assets stood at $1.3 billion in 2021, then fell by 14.15% to $1.1 billion in 2022, then rose by 10.81% to $1.2 billion in 2023, then decreased by 27.49% to $878.1 million in 2024, then soared by 44.47% to $1.3 billion in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $1.3 billion, $1.1 billion, and $1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.